建国70年来结核病化学治疗的历史进程要览

doi:10.3969/j.issn.1000-6621.2019.11.001

摘要/Abstract

摘要：

结核病是一种古老的传染病,人类与其进行了长期的、艰苦卓绝的斗争,对结核病化学治疗的历史进程值得回顾与总结。随着中华人民共和国的成立及建国70年来我国各个方面的发展,从20世纪50年代初期第一代抗结核化学治疗药物及化学治疗方案的问世,到如今的抗结核新药的研发、问世,以及具有全新机制的化疗药物及治疗方案(包括预防性治疗)的探索、改进、完善,建国70年来结核病化学治疗的进展无不印证着人类彻底控制结核病的历程。

关键词: 结核, 药物疗法, 结核,抗多种药物性, 泛耐药结核病, 临床方案, 周年纪念日和特殊事件, 评论

Abstract:

Tuberculosis (TB) is an ancient disease. The historical process of chemotherapy of tuberculosis is worth reviewing and summing up due to its occurrence and development accompanied with human long term and arduous struggle against TB. With the founding of the People’s Republic of China and the development of various aspects of our country in the past 70 years, and from the advent of the first generation of anti-tuberculosis chemotherapy drugs and chemotherapy regimen in the early 1950s, to the research and development of new anti-tuberculosis drugs, as well as the exploration, improvement and perfection of chemotherapy regimen including preventive treatment, the progress of chemotherapy for tuberculosis in the 70 years since the founding of the People’s Republic of China confirms the course of complete control of tuberculosis in human history.

Key words: Tuberculosis, Drug therapy, Tuberculosis, multidrug-resistant, Extensively drug-resistant tuberculosis, Clinical protocols, Anniversaries and special events, Comment

范琳,熊坤龙,肖和平. 建国70年来结核病化学治疗的历史进程要览[J]. 中国防痨杂志, 2019, 41(11): 1145-1148. doi: 10.3969/j.issn.1000-6621.2019.11.001

FAN Lin,XIONG Kun-long,XIAO He-ping. Historic review of anti-tuberculosis chemotherapy during seventy years of the People’s Republic of China[J]. Chinese Journal of Antituberculosis, 2019, 41(11): 1145-1148. doi: 10.3969/j.issn.1000-6621.2019.11.001

参考文献 26

[1]	The Nobel Prize Organization. Selman A. Waksman Facts. [2019-09-29]. Stockholm: The Nobel Prize Organization, 2019. .
[2]	Lehmann J . The treatment of tuberculosis in Sweden with para-aminosalicylic acid; a review. Dis Chest, 1949,16(6):684-703. doi: 10.1378/chest.16.6.684 URL pmid: 15396516
[3]	Kauffman GB . Isoniazid-destroyer of the white plague. J Chem Educ, 1978,55(7):448-449. doi: 10.7717/peerj.8069 URL pmid: 31788355
[4]	Tucker WB, Livings DG . Isoniazid, streptomycin, and para-aminosalicylic acid compared as two- drug regimens in the treatment of pulmonary tuberculosis among previously untreated patients. Am Rev Tuberc, 1955,72(6):756-782. doi: 10.1164/artpd.1955.72.6.756 URL pmid: 13268848
[5]	Ormerod LP, Harrison JM, Wright PA . Drug resistance in Mycobacterium tuberculosis: a survey over 25 years in Blackburn. Thorax, 1986,41(12):946-950. doi: 10.1136/thx.41.12.946 URL pmid: 3109053
[6]	段连山 . 抗结核药物的研究进展. 四川生理科学杂志, 1998,20(4):11-14.
[7]	Bobrowitz ID, Robins DE . Ethambutol-isoniazid versus PAS-isoniazid in original treatment of pulmonary tuberculosis. Am Rev Respir Dis, 1967,96(3):428-438. doi: 10.1164/arrd.1967.96.3.428 URL pmid: 6039097
[8]	Sensi P . History of the development of rifampin. Rev Infect Dis, 1983,5 Suppl 3: S402-406. doi: 10.1186/s12941-018-0283-8 URL pmid: 29970076
[9]	Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. . Lancet, 1972,1(7760):1079-1085. URL pmid: 4112569
[10]	高静韬, 刘宇红, 李亮 , 等. 从链霉素到贝达喹啉:抗结核药物临床试验发展70年历程回顾. 结核病与肺部健康杂志, 2016,5(1):14-18.
[11]	中国防痨协会. 耐多药结核病化学治疗的意见. 中国防痨杂志, 2003,25(1):4-9.
[12]	World Health Organization . Guideline for the programmatic-management of drug resistant tuberculosis. Geneva: World Health Organization, 2006. doi: 10.1055/s-0032-1333546 URL pmid: 26290923
[13]	World Health Organization . Guideline for the programmatic-management of drug resistant tuberculosis. Geneva: World Health Organization, 1996. doi: 10.1055/s-0032-1333546 URL pmid: 26290923
[14]	World Health Organization . Guidelines for the programmatic management of drug-resistant tuberculosis emergency update 2008. Geneva: World Health Organization, 2008. URL pmid: 26290923
[15]	World Health Organization . Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2014. URL pmid: 25320836
[16]	中国防痨协会. 耐药结核病化学治疗指南(2009). 中国防痨杂志, 2010,32(4):181-198.
[17]	中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015,37(5):421-469.
[18]	World Health Organization . WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016. doi: 10.4046/trd.2017.0049 URL pmid: 28905529
[19]	World Health Organization . WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019. doi: 10.4103/ijmr.IJMR_579_19 URL pmid: 31249191
[20]	中国防痨协会. 耐药结核病化疗治疗指南(2019年简版). 中国防痨杂志, 2019,41(10):1025-1073.
[21]	唐神结, 刘一典, 张占军 , 等. 选择耐多药结核病化疗方案的若干问题. 中国防痨杂志, 2014,36(7):511-514.
[22]	Matsumoto M, Hashizume H, Tomishige T , et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med, 2006,3(11):e466. doi: 10.1371/journal.pmed.0030466 URL pmid: 17132069
[23]	Hwang TJ, Wares DF, Jafarov A , et al. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Int J Tuberc Lung Dis, 2013,17(10):1257-1266. doi: 10.5588/ijtld.12.0863 URL pmid: 23735593
[24]	Yu X, Zeng X, Shi W, et al. Validation of cycloserine efficacy in treatment of multidrug-resistantand extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother, 2018, 62(3). pii:e01824-17. doi: 10.1128/AAC.01824-17 URL pmid: 29311073
[25]	Tang S, Yao L, Hao X , et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis, 2015,60(9):1361-1367. doi: 10.1093/cid/civ027 URL pmid: 25605283
[26]	肖和平, 方勇, 范琳 , 等. 耐药结核病化学治疗研究的过去、现状与未来. 中国防痨杂志, 2014,36(8):634-637. doi: 10.3969/j.issn.1000-6621.2014.08.003 URL